Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Results from a major clinical trial involving 142,000 NHS patients in the UK revealed that the Galleri multi-cancer blood test did not meet its primary objective of reducing late-stage cancer diagnoses. This outcome was presented at an oncology conference in Chicago, highlighting the test's limitations in early cancer detection.
WPN Brief
- What Happened
Results from a major clinical trial involving 142,000 NHS patients in the UK revealed that the Galleri multi-cancer blood test did not meet its primary objective of reducing late-stage cancer diagnoses. This outcome was presented at an oncology conference in Chicago, highlighting the test's limitations in early cancer detection.
- Why It Matters
The failure of the Galleri test to achieve its goal raises concerns about its effectiveness in improving cancer screening practices. This development may impact future research and investment in multi-cancer detection technologies, as well as patient outcomes in oncology.